Professor Nick Wareham

Director CEDAR, Director MRC Epidemiology Unit

01223 330315

Department of MRC Epidemiology
University of Cambridge School of Clinical Medicine
Box 285 Institute of Metabolic Science
Cambridge Biomedical Campus
Cambridge, CB2 0QQ


  • PhD (Epidemiology), University of Cambridge, 1997
  • MSc (Community Medicine),  University of London, 1991
  • MBBS (Medicine), University of London, 1986

Background and experience
Nick is Director of CEDAR, as well as Director of the MRC Epidemiology Unit in the University of Cambridge. He is an Honorary Consultant at Addenbrooke’s Hospital, Cambridge and Co-Director of the Institute of Metabolic Science. He was formerly a Wellcome Trust Senior Fellow in Clinical Science in Cambridge. He qualified in medicine from St Thomas’ Hospital Medical School, London, and trained in epidemiology and public health at the London School of Hygiene and Tropical Medicine, London, Harvard University, Boston, USA and at the University of Cambridge. Nick was Chair of the NICE Programme Development Group on the prevention of prediabetes.  In 2009 he was a member of the WHO Expert Group on the classification and diagnosis of diabetes.

Current work and interests
Nick undertakes research into the aetiological determinants of diabetes, obesity and related metabolic disorders, and the translation of that epidemiological understanding into preventive action. He is a Principal Investigator on the EPIC-Norfolk study and leads the working group for diabetes, obesity and physical activity in EPIC-Europe study. He is the co-ordinator of the InterAct EU FP6 funded project, which aims to investigate how genes and lifestyle factors interact to lead to type 2 diabetes. He has a programme of research into the genetic basis of obesity and type 2 diabetes as part of the Genetics of Energy Metabolism (GEM) consortium. His work on gene-environment interaction is based on quantitative trait studies and large scale population-based cohort studies. A key element of this work is the accurate measurement of lifestyle exposures including physical activity and he has developed and evaluated novel methods for measuring energy expenditure in free-living individuals in population-based studies. He is co-lead of the ADDITION study, a trial of screening for diabetes and intensive cardiovascular risk reduction undertaken in 3 European countries.


Nick’s CEDAR publications here.

Professional membership and roles

  • MRCP (Membership of the Royal College of Physicians), 1990
  • MFPHM (Membership of the Faculty of Public Health Medicine), 1992
  • Accreditation in Public Health Medicine, 1995
  • FRCP (Fellowship of the Royal College of Physicians), 2003
  • FFPHM (Fellowship of the Faculty of Public Health Medicine), 2003
  • Kroc Lecturer and Award, University of Uppsala, 2007
  • Joseph J Hoet Memorial Lecturer and Menarini Award, 5th World Congress on Prevention of Diabetes and its Complications, 2008
  • Chair, NICE Programme Development Group on the prevention of prediabetes.
  • BHF Chairs & Programme Grants Committee
  • MRC Population Health Sciences Group
  • NIHR Public Health Research Funding Board
  • NICE Programme Development Group Type 2 Diabetes Mellitus
  • MRC International Nutrition Group’s Scientific Advisory Committee (ING)
  • BHF UK Physical Guidelines Co-ordination Group
  • NETSCC HTA Obesity Themed Call Board
  • MRC Initiative to establish UK Regional Hubs for Clinical Trials Methodology Research (HTMR)
  • Office for Strategic Co-ordination of Health Research (OSCHR) PHRB Board
  • DIAMAP Scientific Expert Advisory Board
  • Diabetes UK Research Committee
  • MRC National Survey Health and Development (NHSD) Board
  • MRC Health Services and Public Health Research Board (PHROG)
  • MRC Physical Systems and Clinical Services Board
  • UKCRC Planning for Public Health Research in Physical Activity
  • Editorial Board, Diabetologia

Ongoing grants

  • Ref not available,  Forouhi, Wareham et al. MRC, total funding: £77,000. Making the EPIC Food Frequency Questionnaire Accessible and Usable to the End-user. Role: Co-PI. 01/10/09-30/09/2011.
  • Ref not available Griffin, Wareham et al. NIHR, total funding: £500k. Anglo-Danish-Dutch study of Intensive Treatment of people with Newly diagnosed diabetes in primary care (ADDITION) – effects on cardiovascular events at five years. Role: Co-PI. 01/01/10-30/0612.
  • G0800270 Danesh (PI). MRC/BHF, total funding: €2.8M.Study of the interplay of genetic, biochemical, and lifestyle factors on coronary heart disease incidence. Role: Partner. 07/07/09-30/06/13.
  • G950223 Khaw (PI), MRC, total funding: £1.99M. Diet, lifestyle and biological determinants of health and chronic disease in a prospective population study. Role: Co-PI.01/01/06-31/12/10.
  • LSHM-CT-2006-037 Wareham (PI). European Union, total funding: €10M. INTERACT. A study of the interaction of genetic and lifestyle factors on the incidence of type 2 diabetes. Role:  PI. 01/10/06-30/09/11.
  • RP-PG-0606-1259 Griffin (PI). NIHR, total funding: £1M.Reducing the burden of type 2 diabetes translating epidemiology and behavioural science into preventive action. Role:  Co-PI. 01/09/07-30/08/10.
  • Ref not available Wareham (PI). UKCRC, total funding:  £5M.Centre of Excellence in Diet and Physical Activity Public Health Research. Role:  PI.  10/08-09/13.
  • PG/07/108/23369 Loos (PI). BHF, total funding £279k. Investigating the genetic determinants of daily physical activity. Role:  Co-PI. 03/08-02/12
  • Ref not available Wareham, Griffin (PIs). DSF, total funding:  £1.47M. ADDITION Europe. Role:  Co-PI. 10/09-09/11

Completed grants

  • Ref not available Griffin (PI). MRC/NPRI, total funding: 392k £.Environmental and social influences on physical activity. Role:  Partner. 01/06/06-31/05/09.
  • 6438 EPIC Consortium (PI). European Union, total funding: 1M €. European prospective investigation into cancer, chronic disease, nutrition and lifestyle. Role:  Partner. 01/01/06-31/12/09.
  • 2005/50 Wareham (PI). World Cancer Research Fund, total funding: 53k £.Identification of the sub-dimensions of physical activity that are associated with risk of incident cancer in population-based cohort studies. Role:  PI. 010106-31/12/08
  • FOOD-CT-2005-513946 DIOGenes Consortium (PI). European Union, total funding: 14M €. Diet, Obesity and Genes ‘DIOGenes’. Role:  Partner. 01/01/05-1/12/09.
  • 074786/Z/04/Z Wareham (PI). Wellcome Trust, total funding: 95k £. Development and validation of feasible methods for measuring physical activity in population studies in Africa. Role:  PI. 01/10/04-30/06/07.
  • Ref Davies (PI). The ADDITION Study Leicester: A randomised controlled trial of the cost effectiveness of a screening and intensive and multi-factorial intervention programme of type 2 diabetes mellitus. NHS R&D, total funding: 1.824 M £. Role: Co-PI. 01/04/04-31/03/07.
  • WT 067457 Wareham (PI).  Wellcome Trust, total funding: 1.5 M £. Epidemiological contribution to the primary prevention and early detection of type 2 diabetes. Role:  PI. 01/07/02-31/12/08.
  • C8648A3883 Khaw (PI). Cancer Research UK, total funding: 1.0 M £. Diet and cancer: Prospective population study in East Anglia and European Prospective Investigation into Cancer (EPIC). Role:  Co-PI. 01/04/02-21/03/07.
  • G0001164 Griffin (PI). Does adding facilitated behaviour change improve outcomes in people with diabetes detected by screening? The ADDITION study. MRC, total funding: 538k £. Role: Co-PI. 01/10/01-30/04/07.
  • Ref not available Kinmonth (PI). MRC (Co-op grant), total funding: 261k £. Development and evaluation of innovative strategies for the prevention of chronic disease in primary care. Role:  Co-PI. 01/01/03-31/12/07.
  • G9800062 Wareham (PI). MRC (Co-op grant), total funding: 245k £. Environment Gene Interaction in Chronic Disease. Role:  PI. 20/01/99-19/06/06.
  • G0701863 Wareham (PI). MRC-GSK pilot grant, total funding: 1M £. MRC-GSK pilot programme to identify new targets and biomarkers from genetic association studies. Role:  PI. 01/01/00-31/12/09.

Organisational affiliation

External links